These benefits appear quickly after initiation of treatment with semaglutide in people with overweight or obesity and a history of atherosclerotic heart disease, suggesting that GLP-1 medicines may reduce cardiovascular events in part through weight loss–independent mechanisms (62). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.